Quantcast

Contract Research Organization WCCT Global Announces Southern California Clinical Trial Volunteer Reach of Over 240,000 People with the use of Facebook Page Following

April 3, 2014

Great milestones for patient recruitment have been achieved through WCCT Global’s Social Media Following

COSTA MESA, Calif., April 3, 2014 /PRNewswire-iReach/ — WCCT Global (WCCTG), a contract research organization headquartered in Southern California announced today that due to their quickly growing Facebook page following of clinical trial volunteers, they now have the ability to directly reach over 240,000 people. The use of social media (SM) for clinical trial patient recruitment has been controversial because many organizations have tried to use SM for patient recruitment but were unable to demonstrate its’ usefulness. Also, many argue that only the “younger” generation use SM. However, recent metrics actually demonstrate that the fastest growing age group subscribing to SM is the 45-54 age group and WCCTG has demonstrated these increased subscription numbers by its’ current efforts for recruiting ongoing trials. WCCT Global saw the opportunity to use social media to directly reach out to people who may be unaware of ongoing clinical trials for their “ailment” and have directly promoted WCCTG ongoing trials to this specific age group. WCCT Global has now established, through SM, a new tool that can facilitate recruitment of a large engaged network of “followers” who are interested in participating in clinical trials. The real power they say is not only in their initial following of volunteers but the ability to introduce their clinical trials to their social followers’ “connections”. WCCT Global’s Digital Media and Marketing Manager Matt Miller stated, “If you combine the value of a single Facebook follower and all of their connections, we are able to introduce clinical trials to our “followers” plus their connections. Assuming that the average person has over 100 connections on Facebook, imagine the instant reach you would have with a social media page of over 10,000!”

(Logo: http://photos.prnewswire.com/prnh/20140403/MN96760)

WCCT Global has introduced this “reach” to clients that choose them for their site, CRO, or patient recruitment services. They point out that any clinical trials that are in need of instant response of volunteers, that they are able to introduce the clinical trial to over 240,000 potential trial participants. WCCT Global announced this local reach after recently announcing their specialized recruitment service called “In-Site“. “In-Site” is designed to assist clients in selecting sites based on patient concentration and cover every aspect of early or late phase clinical trial recruitment.

More about WCCT Global:

WCCT Global is a multi-site, full-service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting-edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines.

If you are interested in learning more about WCCT Global and their clinical research services, CLICK HERE.

Media Contact: Matt Miller, WCCT Global, 714.668.1500 ext.2029, Matt.Miller@wcct.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE WCCT Global


Source: PR Newswire



comments powered by Disqus